The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Anti-CD3/CD7 immunotoxins for the treatment of steroid-refractory acute graft-versus-host disease
Christoph Groth, University Hospital of Muenster, Muenster, Germany, and colleagues conducted a phase I/II trial to evaluate the safety and efficacy of an immunotoxin-combination, a mixture of anti-CD3 and anti-CD7 antibodies separately conjugated to recombinant ricin A (CD3/CD7-IT) for the treatment of patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD). This immunotoxin-combination causes in-vivo depletion of T- and NK-cells and regulates T-cell receptor activation. The findings of this study were published ahead of print in the Biology of Blood and Marrow Transplantation.
Patients received 4 mg/m2 CD3/CD7-IT in four 4-hour intravenous infusions administered at 48-hour intermissions. GvHD prophylaxis included cyclosporine-A alone or in combination with mycophenolate mofetil. Prophylaxis was continuously administered during treatment with CD3/CD7-IT.
Patient characteristics:
- N = 20 patients with SR-aGvHD, 85% of these had severe SR-aGvHD
- Median age: 53 years (range, 18–74)
- All patients had visceral organ involvement:
- N = 18 gastrointestinal (GI)
- N = 5 liver (25%) involvement
Key findings:
- Median follow-up: 292 days (range, 3–889)
- Two patients died of disease progression before completing treatment
- N = 18 patients (90%) received all four scheduled doses of therapy
- Overall response rate: 60% (95% CI, 36–81%)
- Complete response rate: 50% (95% CI, 27–73%)
- 6-month overall survival rate: 60% (95% CI, 36–78%)
- Eight patients died on trial due to refractory aGvHD (4 patients), refractory GvHD with infection (3 patients), and pseudomembranous colitis (1 patient)
- Treatment-related AEs included hypoalbuminemia, microangiopathy, and thrombocytopenia
- One-week treatment course led to T- and NK-cell depletion with rapid recovery of the immune system
This study indicates that CD3/CD7-IT is safe with “relatively low prevalence of manageable and reversible adverse events, primarily worsening of hypoalbuminemia, microangiopathy, and thrombocytopenia” for SR-aGvHD patients. Furthermore, this data suggests that CD3/CD7-IT is a promising treatment option for patients with SR-aGvHD.
References